Bausch Health sets 2025 outlook at the higher end of the prior range
2026-01-13 10:54:37 ET
More on Bausch Health Companies
- Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
- Bausch Health: Solid Q3 Performance Reinforces Deleveraging Path
- Why Bausch Health Is A Buy After Rising 10% On Third Quarter Results
- Carl Icahn's top Q3 moves include new stake in EchoStar, exiting Bausch Health
- Bausch Health raises 2025 revenue guidance to $5B-$5.1B while strengthening Solta and Salix growth
Read the full article on Seeking Alpha
For further details see:
Bausch Health sets 2025 outlook at the higher end of the prior rangeNASDAQ: BHC
BHC Trading
-1.63% G/L:
$4.99 Last:
812,834 Volume:
$5.10 Open:



